-
-
-
-
-
-
-
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
-
-
-
-
-
-
-
Morgan Stanley Assumes Recursion Pharmaceuticals (RXRX) at Equalweight
-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Misses Q4 EPS by 12c
-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c
-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 4c
-
-
-
-
-
-
-
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) Granted FDA Fast Track Designation for REC-4881
-
1,199,546 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

